Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate ...

ModeX Therapeutics Inc., an OPKO Health company, announces dosing of the first participant in the phase I study (NCT06655324) of an Epstein-Barr virus (EBV) vaccine candidate being developed in ...